

BIB - The Nasdaq Stock Market

Semi-annual Shareholder Report – November 30, 2024

This Semi-annual shareholder report contains important information about Ultra Nasdaq Biotechnology (the “Fund”) for the period of June 1, 2024 to November 30, 2024. You can request additional information about the Fund by contacting us at 866-776-5125. You can also find additional information about the Fund at: https://www.proshares.com/geared_shareholder_reports.

What were the Fund's costs for the period?

(based on a hypothetical \$10,000 investment)

Ticker	Costs of a \$10,000 investment	Costs paid as a percentage of a \$10,000 investment*
BIB	\$49	0.95%
* Annualized		

Key Fund Statistics

Net Assets	\$77,493,238
Number of Portfolio Holdings	223
Portfolio Turnover Rate	6%

Market Exposure

Investment Type	% of Net Assets
Equity Securities	71%
Swap Agreements	129%
Total	200%

“Market Exposure” includes the value of total investments (including the contract value of any derivatives) and excludes any short-term investments and cash equivalents.

Sector Weights

Sector	% of Exposure
Biotechnology	80.7%
Pharmaceuticals	14.5%
Life Sciences Tools & Services	4.1%
Health Care Providers & Services	0.5%
Health Care Equipment & Supplies	0.2%

Largest Holdings

Holdings	% of Net Assets
Gilead Sciences, Inc.	7.0%
Vertex Pharmaceuticals, Inc.	5.6%
Amgen, Inc.	5.1%
Regeneron Pharmaceuticals, Inc.	3.8%
AstraZeneca plc (ADR)	2.8%
Alnylam Pharmaceuticals, Inc.	2.4%
Biogen, Inc.	1.7%
Illumina, Inc.	1.7%
Argenx SE (ADR)	1.4%
Moderna, Inc.	1.2%

Ultra Nasdaq Biotechnology - BIB

Semi-annual Shareholder Report – November 30, 2024

If you wish to view additional information about the Fund; including but not limited to financial statements or holdings, please visit www.proshares.com or by calling ProShares Trust at 866-776-5125.



BIB1124